real-time news and commentary for investors
Wednesday, May 1
Forest Laboratories (FRX) and Almirall announce positive topline results from a second six-month...
Forest Laboratories (FRX) and Almirall announce positive topline results from a second six-month Phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair inhaler. Results showed the combination demonstrated statistically significant improvements in change from baseline for the co-primary endpoints.